Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Initiation of Systemic Therapy During the Last 30 Days of Life in Patients With Metastatic Castration-resistant Prostate Cancer.

Nieder C, Haukland E, Mannsåker B, Pawinski A, Yobuta R, Norum J.

Anticancer Res. 2019 Jan;39(1):335-340. doi: 10.21873/anticanres.13116.

PMID:
30591477
2.

Addressing taxane resistance in metastatic castration-resistant prostate cancer: a focus on chaperone proteins.

Hotte SJ.

Future Oncol. 2017 Feb;13(4):369-379. doi: 10.2217/fon-2016-0279. Epub 2016 Oct 7. Review.

PMID:
27712093
3.

Systemic therapy in men with metastatic castration-resistant prostate cancer: a systematic review.

Loblaw DA, Walker-Dilks C, Winquist E, Hotte SJ; Genitourinary Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-Based Care.

Clin Oncol (R Coll Radiol). 2013 Jul;25(7):406-30. doi: 10.1016/j.clon.2013.03.002. Epub 2013 Apr 12. Review.

PMID:
23587782
4.

The influence of prednisone on the efficacy of docetaxel in men with metastatic castration-resistant prostate cancer.

Teply BA, Luber B, Denmeade SR, Antonarakis ES.

Prostate Cancer Prostatic Dis. 2016 Mar;19(1):72-8. doi: 10.1038/pcan.2015.53. Epub 2015 Nov 17.

5.

Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial.

Beer TM, Hotte SJ, Saad F, Alekseev B, Matveev V, Fléchon A, Gravis G, Joly F, Chi KN, Malik Z, Blumenstein B, Stewart PS, Jacobs CA, Fizazi K.

Lancet Oncol. 2017 Nov;18(11):1532-1542. doi: 10.1016/S1470-2045(17)30605-8. Epub 2017 Oct 9.

PMID:
29033099
6.

Optimal sequencing of docetaxel and abiraterone in men with metastatic castration-resistant prostate cancer.

Maughan BL, Xhou XC, Suzman DL, Nadal R, Bassi S, Schweizer MT, Antonarakis ES.

Prostate. 2015 Nov;75(15):1814-20. doi: 10.1002/pros.23064. Epub 2015 Aug 26.

PMID:
26306637
7.

Oncological outcome of docetaxel-based chemotherapy for Japanese men with metastatic castration-resistant prostate cancer.

Miyake H, Sakai I, Terakawa T, Harada K, Fujisawa M.

Urol Oncol. 2013 Aug;31(6):733-8. doi: 10.1016/j.urolonc.2011.06.006. Epub 2011 Jul 22.

PMID:
21782481
8.

Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302.

de Bono JS, Smith MR, Saad F, Rathkopf DE, Mulders PFA, Small EJ, Shore ND, Fizazi K, De Porre P, Kheoh T, Li J, Todd MB, Ryan CJ, Flaig TW.

Eur Urol. 2017 Apr;71(4):656-664. doi: 10.1016/j.eururo.2016.06.033. Epub 2016 Jul 9.

9.

A multicenter retrospective analysis of sequential treatment of abiraterone acetate followed by docetaxel in Japanese patients with metastatic castration-resistant prostate cancer.

Ueda Y, Matsubara N, Takizawa I, Nishiyama T, Tabata K, Satoh T, Kamiya N, Suzuki H, Kawahara T, Uemura H.

Jpn J Clin Oncol. 2015 Aug;45(8):774-9. doi: 10.1093/jjco/hyv070. Epub 2015 May 15.

PMID:
25981621
10.

Efficacy of docetaxel-based chemotherapy following ketoconazole in metastatic castration-resistant prostate cancer: implications for prior therapy in clinical trials.

Pond GR, Armstrong AJ, Galsky MD, Wood BA, Leopold L, Sonpavde G.

Urol Oncol. 2013 Nov;31(8):1457-63. doi: 10.1016/j.urolonc.2012.02.008. Epub 2012 May 1.

PMID:
22552048
11.

Phase 1b Study of Abiraterone Acetate Plus Prednisone and Docetaxel in Patients with Metastatic Castration-resistant Prostate Cancer.

Tagawa ST, Posadas EM, Bruce J, Lim EA, Petrylak DP, Peng W, Kheoh T, Maul S, Smit JW, Gonzalez MD, De Porre P, Tran N, Nanus DM.

Eur Urol. 2016 Nov;70(5):718-721. doi: 10.1016/j.eururo.2016.01.028. Epub 2016 Feb 3.

PMID:
26852075
12.

First-line treatment in senior adults with metastatic castration-resistant prostate cancer: A prospective international registry.

Droz JP, Efstathiou E, Yildirim A, Cabrera P, Soo Kim C, Horchani A, Heidenreich A, Rinck-Junior JA, Hitier S, Ӧzen H.

Urol Oncol. 2016 May;34(5):234.e21-9. doi: 10.1016/j.urolonc.2015.12.005. Epub 2016 Jan 14.

PMID:
26777260
13.

Docetaxel-related toxicity in metastatic hormone-sensitive and metastatic castration-resistant prostate cancer.

Schweizer MT, Gulati R, Mostaghel EA, Nelson PS, Montgomery RB, Yu EY, Cheng HH.

Med Oncol. 2016 Jul;33(7):77. doi: 10.1007/s12032-016-0793-1. Epub 2016 Jun 14.

14.

Treatment outcome of docetaxel plus prednisolone for metastatic castration-resistant prostate cancer in Korea.

Cho IC, Joung JY, Seo HK, Chung J, Park WS, Lee KH.

J Cancer Res Ther. 2014 Apr-Jun;10(2):251-7. doi: 10.4103/0973-1482.136546.

15.

Docetaxel Activity in the Era of Life-prolonging Hormonal Therapies for Metastatic Castration-resistant Prostate Cancer.

Francini E, Sweeney CJ.

Eur Urol. 2016 Sep;70(3):410-2. doi: 10.1016/j.eururo.2016.05.002. Epub 2016 May 13. Review.

PMID:
27184379
16.

No significant impact of response to prior androgen receptor-axis-targeted agents on the efficacy of subsequent docetaxel in patients with metastatic castration-resistant prostate cancer.

Miyake H, Matsushita Y, Tamura K, Motoyama D, Ito T, Sugiyama T, Otsuka A.

Int J Clin Oncol. 2018 Jun;23(3):576-583. doi: 10.1007/s10147-017-1230-y. Epub 2017 Dec 23.

PMID:
29275450
17.
18.

Initial biopsy Gleason score as a predictive marker for survival benefit in patients with castration-resistant prostate cancer treated with docetaxel: data from the TAX327 study.

van Soest RJ, de Morrée ES, Shen L, Tannock IF, Eisenberger MA, de Wit R.

Eur Urol. 2014 Aug;66(2):330-6. doi: 10.1016/j.eururo.2013.08.007. Epub 2013 Aug 11.

PMID:
23957945
19.

Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial.

Petrylak DP, Vogelzang NJ, Budnik N, Wiechno PJ, Sternberg CN, Doner K, Bellmunt J, Burke JM, de Olza MO, Choudhury A, Gschwend JE, Kopyltsov E, Flechon A, Van As N, Houede N, Barton D, Fandi A, Jungnelius U, Li S, de Wit R, Fizazi K.

Lancet Oncol. 2015 Apr;16(4):417-25. doi: 10.1016/S1470-2045(15)70025-2. Epub 2015 Mar 3.

PMID:
25743937
20.

Metronomic therapy in metastatic castrate-resistant prostate cancer: Experience from a tertiary cancer care center.

Dabkara D, Ganguly S, Biswas B, Ghosh J.

Indian J Cancer. 2018 Jan-Mar;55(1):94-97. doi: 10.4103/ijc.IJC_346_17.

Supplemental Content

Support Center